DelMar Pharmaceuticals (NASDAQ: DMPI) is a clinical and commercial stage drug development company with a focus on the treatment of cancer in patients that are failing or have become intolerant to modern targeted or biologic treatments. The company’s lead drug in development is undergoing clinical trials in the United States. Pre-clinical and clinical data suggest that it may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients. For more information, visit the company’s website at www.delmarpharma.com